Stockscreener 앱 받기
2.72
4.56%
-0.13
시간 외 거래:
2.71
-0.01
-0.37%
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborationsICYMI - Proactive Investors USA
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships - Proactive Investors USA
Earnings call: Lisata Therapeutics reports on Q3 progress and trials - Investing.com
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2024 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost Management Success - GuruFocus.com
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... By GuruFocus - Investing.com Canada
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... - Yahoo Finance
Lisata Therapeutics Reports Q3 2024 Financial Results - TipRanks
Lisata Therapeutics Inc Reports Q3 2024 EPS of $0.59 and Net Los - GuruFocus.com
Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025 - Proactive Investors USA
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
LSTALisata Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Lisata and ValoTx announce melanoma research collaboration - Investing.com
Lisata and ValoTx announce melanoma research collaboration By Investing.com - Investing.com UK
Lisata Therapeutics forms partnership for preclinical cancer immunotherapy study - Proactive Investors USA
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration - The Manila Times
Lisata, Valo Therapeutics Partner on Novel Melanoma Treatment Study | Key Research Collab | LSTA Stock News - StockTitan
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 - The Manila Times
Lisata Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
Lisata Therapeutics to Report Q3 2024 Results: Clinical-Stage Cancer Drug Updates | LSTA Stock News - StockTitan
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapyICYMI - Proactive Investors Australia
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know - MSN
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events - GlobeNewswire
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - Proactive Investors UK
Lisata announces preclinical research agreement to study certepetide with bevacizumab for endometriosis - BioWorld Online
Lisata Therapeutics Announces Sponsored Preclinical - GlobeNewswire
Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis - Proactive Investors USA
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis - GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events - The Manila Times
Lisata Therapeutics reiterates stock target, buy rating amid trial update - Investing.com India
Troy Wichterman Sells 611 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock - Defense World
Biolife Solutions exec sells over $77k in company stock - Investing.com India
Bilibili Inc. (NASDAQ:BILI) Short Interest Update - Defense World
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Down 7.1% in August - Defense World
Lisata Therapeutics reiterates stock target, buy rating amid trial update By Investing.com - Investing.com Canada
Market cap of Bilibili Inc ADR [BILI] reaches 4.87B – now what? - The DBT News
BLFS (Biolife Solutions Inc) may reap gains as insiders became active recently - Knox Daily
Daiwa Securities Group Inc. Has $71,000 Stock Position in Bilibili Inc. (NASDAQ:BILI) - Defense World
Short Interest in Bilibili Inc. (NASDAQ:BILI) Drops By 8.3% - MarketBeat
FDA Approves Ebglyss for Treatment of Moderate to Severe Atopic Dermatitis - Managed Healthcare Executive
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update - MarketBeat
Lisata Therapeutics Announces First Patient Treated in the - GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial - StockTitan
Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial - Proactive financial news
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children - The Dermatologist
Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis - Patient Care Online
Ebglyss Approved for Moderate to Severe Atopic Dermatitis - Monthly Prescribing Reference
FDA Approves Lebrikizumab for Atopic Dermatitis - Medscape
Lilly gains FDA approval for lebrikizumab for atopic dermatitis - Seeking Alpha
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis - Investors | Eli Lilly and Company
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events - GlobeNewswire
Lisata Therapeutics to present at September investment conferences - Proactive Investors UK
Lisata jumps on FDA orphan drug status for liver cancer drug - MSN
FDA grants Orphan Drug Designation to Lisata's cancer drug - Investing.com India
Lisata Therapeutics (FRA:8NE) Cash Flow from Investing : €23.04 Mil (TTM As of Jun. 2024) - GuruFocus.com
3.66%
1.11%
자본화:
|
볼륨(24시간):